These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22042960)

  • 1. CYP2D6 and tamoxifen: awaiting the denouement.
    Brauch HB; Schroth W; Ingle JN; Goetz MP
    J Clin Oncol; 2011 Dec; 29(34):4589-90; author reply 4590-1. PubMed ID: 22042960
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalized tamoxifen: what is the best way forward?
    Rae JM
    J Clin Oncol; 2011 Aug; 29(24):3206-8. PubMed ID: 21768456
    [No Abstract]   [Full Text] [Related]  

  • 3. Emphasizing the value of phenotyping in patients receiving tamoxifen.
    Opdam FL; Dezentje VO; den Hartigh J; Guchelaar HJ; Gelderblom H
    J Clin Oncol; 2012 Feb; 30(4):464; author reply 465. PubMed ID: 22184383
    [No Abstract]   [Full Text] [Related]  

  • 4. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
    de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
    J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
    Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
    Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.
    Novillo A; Romero-Lorca A; Gaibar M; Rubio M; Fernández-Santander A
    Pharmacogenomics J; 2017 Mar; 17(2):109-111. PubMed ID: 27698402
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
    Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
    Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
    Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
    J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
    Holzman D
    J Natl Cancer Inst; 2009 Oct; 101(20):1370-1. PubMed ID: 19797723
    [No Abstract]   [Full Text] [Related]  

  • 10. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PharmGKB summary: tamoxifen pathway, pharmacokinetics.
    Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE
    Pharmacogenet Genomics; 2013 Nov; 23(11):643-7. PubMed ID: 23962908
    [No Abstract]   [Full Text] [Related]  

  • 13. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
    ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
    Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
    Lyon E; Gastier Foster J; Palomaki GE; Pratt VM; Reynolds K; Sábato MF; Scott SA; Vitazka P;
    Genet Med; 2012 Dec; 14(12):990-1000. PubMed ID: 22955113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
    Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
    Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.
    Young D
    Am J Health Syst Pharm; 2006 Dec; 63(23):2286, 2296. PubMed ID: 17105997
    [No Abstract]   [Full Text] [Related]  

  • 18. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding CYP2D6 and its role in tamoxifen metabolism.
    Smith EC
    Oncol Nurs Forum; 2013 Nov; 40(6):547-8. PubMed ID: 24161632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further characterization of a ¹³C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy.
    Opdam FL; Modak AS; Gelderblom H; Guchelaar HJ
    J Breath Res; 2015 Apr; 9(2):026003. PubMed ID: 25891764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.